Chemotherapy plus anti-PD-1/L1 represents a more effective and tolerable treatment option for advanced, unresectable, and recurrent iCCA patients compared to chemotherapy alone. The gene discussed is PDCD1; the disease is infantile convulsions and choreoathetosis.